Dark
Streaming/Mobile
Old Site
Home
Daily
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:31:48 EDT Thu 30 Mar 2023
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:XFOR from 2022-03-31 to 2023-03-30 - 28 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2023-03-21 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
2023-03-07 08:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
2023-03-02 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-12 08:30
U
U:XFOR
News Release
200
X4 Pharmaceuticals ¢ € ™ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
2022-12-07 08:43
U
U:XFOR
News Release
200
X4 Pharmaceuticals Prices $65.0 Million Public Offering
2022-12-06 18:26
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Proposed Public Offering
2022-11-29 16:01
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
2022-11-08 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present at Stifel Healthcare Conference
2022-11-04 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-03 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-26 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
2022-10-20 08:00
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
2022-09-27 07:50
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN)
2022-08-31 08:30
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia
2022-08-08 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present at Canaccord Genuity's 42nd Annual Growth Conference
2022-08-04 07:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-07-26 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022
2022-07-20 16:10
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones
2022-07-01 16:30
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-30 19:53
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
2022-06-23 07:00
U
U:XFOR
News Release
200
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
2022-05-16 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
2022-05-12 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-03 06:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
2022-05-02 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-08 13:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
2022-04-04 08:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals to Present at April Investor Conferences
2022-04-01 16:05
U
U:XFOR
News Release
200
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)